MHC
VRTX icon

May Hill Capital’s Vertex Pharmaceuticals VRTX Stock Holding History

May Hill Capital’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$255K Sell
571
-95
-14% -$44.3K 0.06% 186
2025
Q4 		$302K Buy
666
+26
+4% +$11.2K 0.08% 150
2025
Q3 		$251K Sell
640
-33
-5% -$13.8K 0.07% 163
2025
Q2 		$300K Buy
673
+40
+6% +$18.4K 0.1% 143
2025
Q1 		$307K Sell
633
-15
-2% -$6.99K 0.12% 122
2024
Q4 		$261K Buy
+648
New +$300K 0.1% 131

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

May Hill Capital's VRTX Position: Q1 2026 in Review

May Hill Capital reduced its Vertex Pharmaceuticals (VRTX) stake by 14% in Q1 2026, selling an estimated $44.3K and leaving 571 shares worth $255K. The position accounts for 0.06% of the portfolio, ranked #186.

May Hill Capital first reported a position in VRTX in Q4 2024 and has held it in 6 quarters since. The position peaked at $307K in Q1 2025. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • May Hill Capital held 571 shares of Vertex Pharmaceuticals worth $255K as of Q1 2026.
  • May Hill Capital sold 95 Vertex Pharmaceuticals shares in Q1 2026, an estimated $44.3K.
  • Vertex Pharmaceuticals made up 0.06% of May Hill Capital's portfolio in Q1 2026, its #186 holding.
  • May Hill Capital first reported a position in Vertex Pharmaceuticals in Q4 2024 and has held it in 6 quarters since.
  • May Hill Capital's Vertex Pharmaceuticals position peaked at $307K in Q1 2025.
  • 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on May Hill Capital's 13F filing for Q1 2026, filed 6 May 2026.